More and more tumor biomarkers, such as PD-L1, BRCA1/2, BRAF, HER2, etc., have been discovered, which become an indispensable tool in current tumor treatment due to its ability to assist various clinical decisions (Zhou et al., 2015). This evidence concerns the gene ERBB2 and neoplasm.